What was Alumis's IPO price?
Alumis, a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for immunology and autoimmune diseases, priced its initial public offering on the Nasdaq Global Select Market at sixteen U.S. dollars per share. Operating previously under the name Esker Therapeutics before rebranding, the company offered over thirteen million shares to raise approximately two hundred and fifty million dollars in gross proceeds during its market debut. This milestone offering valued the enterprise at roughly nine hundred million dollars, providing critical financial capital required to advance its robust pipeline of oral tyrosine kinase 2 inhibitors through advanced clinical trials targeting severe dermatological and systemic autoimmune conditions.
Related FAQs
Amicus Therapeutics, Inc. maintains a specialized global workforce of approximately 500 to 600 employees.
Yes, in October 2024, the Abu Dhabi National Oil Company (ADNOC) successfully completed its acquisition of a majority stake in Fertiglobe.
Alumis Inc. reports an annualized trailing revenue of approximately $24.05 million USD, reflecting its dynamic stage as a clinical-stage biopharmaceutical company.
Alumis Inc. is a well-capitalized, clinical-stage biopharmaceutical enterprise dedicated to transforming the treatment landscape for patients suffering from severe autoimmune and neuroinflammatory diseases.
Equities or specialized financial instruments trading under designations such as ALMS vary entirely depending on the specific regional stock exchange and corporate entity referenced.
Alumis Inc. operates within the Healthcare sector.
Equity securities and stocks like ALMS do not receive traditional credit ratings, which are instead reserved for debt instruments, bonds, and corporate issuer creditworthiness.
Alumis Inc., a clinical-stage biopharmaceutical company focused on developing precision oral therapies for immune-mediated and neuroinflammatory diseases, has expanded its pipeline and corporate scale through strategic transactions.
Trading volume metrics for specific equities like Almaden Minerals Ltd. (NYSE American: ALMS) vary dynamically based on prevailing market sentiment, macro-economic conditions, and corporate news flow.
When examining growth prospects associated with legacy motorsport properties like the American Le Mans Series (which historically merged into the WeatherTech SportsCar Championship) or specialized corporate entities bearing similar acronyms, financia...
Alumis Inc. trades under the stock ticker symbol ALMS on the NASDAQ global market exchange.
Applied Digital Corporation (operating under the ticker ALMS or similar classifications depending on context) reports financial metrics characterized by heavy capital investments and rapid revenue scaling within the digital infrastructure, high-perfo...
Alumis Inc., a biopharmaceutical company focused on transforming the treatment of immune-mediated diseases through precision medicine and therapeutic innovation, is headquartered in South San Francisco, California, United States.
Alumis anticipates a dynamic future outlook as a clinical-stage biopharmaceutical enterprise advancing precision therapies for immunology and complex autoimmune disorders.
Alumis operates as a clinical-stage biopharmaceutical enterprise specializing in the research, development, and precision commercialization of innovative targeted therapies designed to address complex immune-mediated and autoimmune diseases.
Determining whether Alumis represents a favorable equity purchase involves reviewing fundamental clinical trial milestones, regulatory drug approval progress, and consensus healthcare analyst research ratings.